Rabobank-backed firm Anterra invested $4m to boost the series C funding raised by Vestaron, which produces pesticides from spider venom, to $14m.
Vestaron, a US-based agricultural company commercialising biopesticides developed from spider venom, has extended its series C round by $4m to $14m, securing the funding from venture capital firm Anterra Capital.
Anterra, formerly known as Rabo Ventures, was spun out from Netherlands-based bank Rabobank in October 2013. It is jointly funded by Moonray Investors, a subsidiary of FIL, the parent company of mutual fund manager Fidelity Worldwide Investment, and Rabo Private Equity, Rabobank’s proprietary private equity arm.
Vestaron secured an initial…
